NanoGuardian’s Client Wins Approval for NanoEncryption Technology
NanoGuardian, a division of NanoInk, has announced that the FDA has issued approval to a NanoGuardian client to use NanoGuardian’s NanoEncryption technology as an on-dosage, brand protection technology.
NanoGuardian said that its NanoEncryption technology provides pharmaceutical manufacturers with true forensic, multi-layered, authentication and tracing brand protection at the individual dosage level.
NanoGuardian’s NanoEncryption technology works directly on tablets, capsules and vials and captures a virtually unlimited amount of data including manufacturing information, dosage strength, expiration date and the targeted site of distribution including country, state and specific distributor if desired, said the company.
James Hussey, CEO of NanoInk, said: “FDA approval of our NanoEncryption technology is an important milestone for public health and the continued fight to secure the pharmaceutical supply chain.”